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http://dx.doi.org/10.1016/j.asjsur.20Summary Purpose: Bariatric surgery is an efficient procedure for the remission of type 2 dia-
betes (T2DM) from morbid obesity. However, in Asian countries, the mean body mass index
(BMI) of T2DM patients is about 25 kg/m2. Various data on patients undergoing gastric bypass
surgery suggest that the control of T2DM after surgery occurs rapidly. We hypothesized that
even in nonobese patients with T2DM, the levels of incretin and insulin changed along with
the improvement of T2DM as a consequence of the gastric bypass.
Materials and methods: From March to December 2011, 12 nonobese patients (mean BMI;
26.2 kg/m2) with poorly-controlled [mean glycated hemoglobin (HbA1C); 9.5%] diabetes under-
went gastric bypass surgery. Values related to diabetes, including incretin [gastric inhibitory
peptide (GIP) and glucagon-like peptide-1 (GLP-1)] levels were measured before and 1 month
after surgery. All values were measured in response to a 75 g oral glucose tolerance test
(OGTT).
Results: On average, the BMI decreased by 2.1  0.7 kg/m2. Mean HbA1C level decreased by
1.6  2%. Oral glucose-stimulated insulin levels increased and GLP-1 levels also increased
significantly. Oral glucose-stimulated GIP levels decreased sharply.hors declare no conflict of interest.
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Incretin levels after gastric bypass 131Conclusion: Soon after gastric bypass in nonobese T2DM patients, control of T2DM is achieved.
The incretin release after oral glucose is improved. This could be a consequence of changes of
the enteroinsular axis, particularly in the incretins.
Copyright ª 2013, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The number of people with type 2 diabetes mellitus (T2DM)
is increasing at an alarming rate in every country. In 2011,
the global prevalence of T2DM was estimated at 366 million
(8.3%) of the adult population (age 20e79 years). It is ex-
pected to rise to 552 million (9.9%) by 2030.1
In Western countries, the association between obesity
and T2DM is well established, because 90% of patients with
T2DM show excess body weight.2 However, according to a
recent survey by the Ministry of Health and Welfare of
Korea, the mean body mass index (BMI) of T2DM patients in
Korea is 24.9  3.3 kg/m2.3
Some types of weight loss surgery, especially Roux-en-Y
gastric bypass (RYGB) and biliopancreatic diversion (BPD),
generally result in a loss of about 70% of excess body
weight (68.1% and 72%, respectively) and cure diabetes in
> 80% of the patients.4 It is noted that glycemic control
after weight loss surgery often occurs before a significant
weight loss.5 The recovery of T2DM is due not only to
weight loss and decreased food intake, but also to other
factors closely related to the rerouting of the gastrointes-
tinal tract, the exclusion of the duodenum and jejunum,
and rapid transit of food to the distal part of the small
intestine.6e8
It has been proposed that the enteroinsular axis could
be a major part of the mechanism related to antidiabetic
effects of certain types of bariatric surgery.9 The enter-
oinsular axis means the connection between the gut and
the pancreatic islets. The hormonal part of the axis,
known as “incretin”, is released by nutrients and stimu-
lates insulin secretion. The two main incretins are
glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (gastric inhibitory peptide,
GIP).10,11
Both GLP-1 and GIP enhance meal-related insulin
secretion, known as the “incretin effect”.12e16 In normal
individuals, the release of both GLP-1 and GIP contributes
to the stimulation of insulin secretion after a meal and to
store glucose in the peripheral tissues. However, in all
T2DM patients, the loss of this effect, defined as enter-
oinsular impairment, is characteristic.17 GLP-1 levels are
blunted. Contrary to GLP-1, GIP levels are normal or over-
produced, but the effect of GIP on insulin secretion is
blunted.18
Several studies resulted in successful treatment of T2DM
in nonmorbidly obese diabetes patients after single anas-
tomosis gastric bypass surgery.19,20 However, none of these
studies measure incretins such as GLP-1 and GIP, or report
the incretin effect on insulin secretion in nonmorbidly
obese patients. We aimed to investigate the changes of the
incretin levels in response to oral glucose in nonmorbidlyobese T2DM patients before and 1 month after single
anastomosis gastric bypass.2. Patients and methods
The inclusion criteria for patients in this prospective study
were the following: aged 20e65 years, BMI > 23.0 kg/m2
but < 30.0 kg/m2 (normal to overweight BMI based on the
WHO definition), fasting C-peptide  1.0 ng/mL, and gly-
cated hemoglobin (HbA1C)> 7.0% after 6 months of medical
treatment. We have not stated the duration of diabetes
limits. The exclusion criteria were: type 1 diabetes mellitus,
any contraindication to general anesthesia, any history of
previous gastrointestinal surgery, and the inability to comply
with study protocols or regular follow-up. All patients gave
informed consent and this prospective study was approved
by the institutional review board for Human Research of
Soonchunhyang University Hospital (Number 2011-69).
2.1. Single anastomosis gastric bypass
All patients underwent a laparoscopic single anastomosis
gastric bypass with the 5-trocar method: four 12 mm tro-
cars and one 5 mm trocar. At first, a long vertical and
relatively large gastric tube was made by using endo-
staplers (Endo GIA 60 mm Articulating Medium/Thick
Reload with Tri-Staple Technology, Covidien Autosuture,
Mansfield, MA, USA) along the lesser curvature from 2 cm
proximal to the pylorus aiming towards the gastric fundus.
We did not consider determining the exact size of the
gastric pouch. The volume of the gastric pouch was roughly
adjusted according to the patient’s BMI. We preserved the
gastric fundus in every patient, because there is no need to
restrict food intake in nonmorbid obese patients and
because we need to secure the simplicity and reversibility
of the procedure. We divided the stomach from the distal
lesser curvature that is 2 cm proximal to the pylorus and
made a vertical gastric tube. In patients with BMI > 25 kg/
m2, we made a gastric tube from the distal lesser curva-
ture, passing the upper part of the gastric angle, aiming
towards the gastric fundus. In patients with BMI < 25 kg/
m2, we made a gastric tube aiming towards the gastric
upper body. After the formation of the vertical gastric
pouch, the small intestine, 200 cm distal from the ligament
of Treitz, was anastomosed with a gastric pouch using an
endo-stapler (Endo GIA 45 mm Articulating Vascular/Me-
dium Reload with Tri-Staple Technology, Covidien Autosu-
ture) in a side-to-side, antecolic, isoperistaltic fashion.
Consequently, part of the gastric antrum, duodenum, and
proximal jejunum were bypassed and a side-to-side gas-
trojejunostomy was made (Fig. 1). An anchoring suture was
Figure 1 Illustration of single anastomosis gastric bypass
surgery. The surgeon made a vertical gastric tube and anas-
tomosed it with jejunum 200 cm distal from the ligament of
Treitz.
132 M.J. Kim et al.made between the gastric pouch and the afferent limb for
acute angulation of the afferent limb, maintaining a par-
allel line between the long gastric pouch and the efferent
limb. An intraoperative leak test was performed using air
and blue dye, to confirm a negative leak at the
anastomosis.Table 1 Patient characteristics.
Before surgery
Age (y) 45.4  10.2
Duration (y) 9.1  8.2 (1e
Weight (kg) 73.2  7.8
BMI (kg/m2) 26.2  2.1
HbA1C (%) 9.5  1.6
Fasting glucose (mg/dL) 170.3  45.1
Fasting insulin (mIU/mL) 15.8  11.4
HOMA-IR 6.35  4.37
120-min glucose (mg/dL) 317.2  57.4
Peak insulin (mIU/mL) 49.3  50.0
AUC glucose (mg/dL min1) 281.7  31.7
AUC insulin (uIU/mL min1) 36.0  36.0
AUC total GLP-1 (pmol/L min1) 27.6  13.4
AUC active GLP-1
(pg/mL min1)
108.0  63.0
AUC GIP (pg/mL min1) 184.0  70.0
Data are mean  SD. Peak (during 120-minute value) and AUC (total ar
75 g OGTT.
D Z difference between pre- and post-gastric bypass surgery. BM
1 Z glucagon-like peptide-1; HbA1C Z glycated hemoglobin; HOMA-I2.2. Measurement of insulin, C-peptide and
incretin after 75 g oral glucose tolerance test
2.2.1. Insulin secretion after oral glucose load
All patients underwent 2-hour oral glucose tolerance tests
(OGTTs) with 75 g of glucose in a total volume of 225 mL
before and 1 month after surgery. Blood samples, collected
in chilled EDTA tubes with added aprotinin (500 kallikrein
inhibitory units/mL blood) and dipeptidyl-peptidase IV
(DPPIV) inhibitor (Linco Research Inc., St. Charles, MO, USA)
(10 mL/mL blood), were centrifuged at 4C before being
stored at e70C. Plasma concentrations of glucose, insulin,
C-peptide, total and active GLP-1, and GIP were measured
at 0, 15, 30, 60, 90, and 120 minutes during the 75 g OGTT.
2.2.2. Incretin assay
GLP-1, an indicator of secretion, was measured by ELISA
[Multispecies GLP-1 Total, Millipore (Linco), Billerica, MA,
USA] after plasma ethanol extraction. The intra-assay and
inter-assay coefficients of variation (CVs) were < 5%
and < 12%, respectively. Active GLP-1, an indicator of the
potential action, and total GIP were measured by the
multiplexing method [Milliplex MAP Human Gut Hormone
Panel, Millipore (Linco)]. The intra-assay and inter-assay
CVs were < 11% and < 19%, respectively.
2.3. Statistical analysis
The outcome variables were serum glucose and plasma in-
sulin, C-peptide, GLP-1, and GIP concentrations. Data are
presented as means  SD unless otherwise stated. The total
area under the curve (AUC) values 0e120 minutes for
outcome variables were calculated using the trapezoidal
method. Wilcoxon signed rank-sum tests were used to
compare the data from before and after the surgery.After surgery p (D)
25)
66.7  7.2 0.002
24.1  2.2 0.002
7.9  1.0 0.045
171.0  62.4 0.875
12.6  5.8 0.347
5.23  2.61 0.469
232.3  103.3 0.041
91.9  75.2 0.136
252.4  80.9 0.308
57.0  49.0 0.239
59.1  17.1 <0.0001
311.0  178.0 <0.0001
98.0  35.0 0.002
ea under the curve, 120 minutes) values were obtained during the
I Z body mass index; GIP Z gastric inhibitory peptide; GLP-
R Z homeostasis model assessment-insulin resistance.
Incretin levels after gastric bypass 133Statistical significance was set at p < 0.05. Data were
analyzed using the SPSS version 15.0 for Windows (SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Patients’ characteristics
The patients’ characteristics are shown in Table 1. Twelve
patients (7 males and 5 females), with a mean age of 45.4
years (range 28e63 years), with T2DM of 9.1  8 years
duration (range 1e25 years) were studied before and 1
month after single anastomosis gastric bypass surgery. The
mean BMI was 26.2  2.1 kg/m2 (range 23.1e30.0 kg/m2).
Two patients were treated with insulin and the others with
more than one oral hypoglycemic agent.
3.2. Side effects
No patients experienced severe adverse effects during
OGTTs. No patients experienced stomach cramping or
discomfort, nausea, sweating, flushing or palpitations early
after the ingestion of glucose.
3.3. Changes in body weight and HbA1C levels
The average body weight of the 12 patients was reduced.
The difference in body weight between pre- and post-
gastric bypass surgery was 6.5  2.1 kg in the 1st month
(from 73.2  7.8 kg to 66.7  7.2 kg, p Z 0.002). The
difference in BMI between pre- and post-gastric bypass
surgery was e2.1  0.7 kg/m2 in the 1st month (from
26.2  2.1 kg/m2 to 24.1  2.2 kg/m2).
One month after surgery, the HbA1C levels decreased
significantly (from 9.5  1.6% to 7.9  1.0%, p Z 0.045).
3.4. Changes in requirements for antidiabetic
medications
Notably, at 1 month after surgery, no patients needed in-
sulin injections. Six patients, including two patients whoFigure 2 Glucose, insulin, and C-peptide concentrations during o
not change, while 120-minute glucose levels decreased significant
enhanced than those at baseline. Data are presented as mean 
between values at the same time into the OGTTs before and afterhad used insulin for glucose control, used a decreased
dosage of antidiabetic medications after surgery.
3.5. Glucose and insulin levels during the OGTT
Changes in the outcome variable after surgery are shown in
Table 1. Fasting glucose levels did not change, while 120-
minute glucose levels decreased significantly. Peak insulin
levels and C-peptide levels tended to be more enhanced
than those at baseline (Fig. 2). The AUC of glucose levels
were lowered 1 month after surgery, and the AUC of insulin
1 month after surgery tended to be higher than those at
baseline, although the difference was not significant. The
homeostasis model assessment-insulin resistance (HOMA-
IR), indicator of insulin resistance, decreased slightly.
However, there was no statistical significance.
3.6. GLP-1 and GIP levels during the OGTT
The levels and AUC of total GLP-1 and the levels and AUC of
active GLP-1 increased significantly 1 month after surgery.
The levels and AUC of GIP decreased significantly 1 month
after surgery (Fig. 3). All changes occurred regardless of the
duration of T2DM.
4. Discussion
Type 2 DM is a chronic metabolic disease which leads to a
number of complications. Lifelong diabetes control is
mandatory.21,22 However, the current glycemic control with
antidiabetic medications and intensive lifestyle interven-
tion is unsatisfactory.
Studies in a diabetic rat model suggest that the exclusion
of the upper gut, rather than weight loss, benefits glucose
tolerance.23 This improvement in glucose tolerance was
shown to be independent of weight and food intake. These
rodent studies underline potential mechanisms by which
diabetes can be improved after bariatric surgery and support
a role of the gut incretins in glucose tolerance after RYGB.9
The achievement of glycemic control, along with sig-
nificant excess weight loss, has been reported in diabetic
patients with morbid obesity after bariatric surgery such as
RYGB or BPD.24,25 It was thought that the incretins couldral glucose tolerance tests (OGTTs). Fasting glucose levels did
ly. Peak insulin levels and C-peptide levels tended to be more
SD. GBP Z gastric bypass. )p < 0.05, significant difference
surgery.
Figure 3 Time course for the changes in mean total glucagon-like peptide-1 (GLP-1), active GLP-1, and gastric inhibitory peptide
(GIP) levels and the AUC during an oral glucose tolerance test (OGTT) before and 1 month after surgery. The levels and AUC of total
glucagon-like peptide-1 (GLP-1) and the levels and AUC of active GLP-1 increased significantly 1 month after surgery. The levels and
AUC of gastric inhibitory peptide (GIP) decreased significantly 1 month after surgery. Data are presented as mean  SD. )p < 0.05,
significant difference between values at the same time into the OGTTs before and after surgery.
134 M.J. Kim et al.play a major role in the marked immediate improvements
of diabetes control before weight loss is observed after
bariatric surgery.26
Evidence is growing that gastrointestinal bypass opera-
tions involving the rerouting of the GI tract can induce T2DMremission, independent of any weight loss, in a proportion of
patients, and this phenomenon can occur even in the non-
morbidly obese patient.27,28 The GI tract plays an important
role in energy regulation, and many gut hormones are
involved in the regulation of glucose metabolism,29,30 also
Incretin levels after gastric bypass 135known as the incretin effect. In addition, recent data sug-
gest that high glycemic index foods may lead to a hormon-
ally hyperactive proximal gut and a hypoactive distal gut,
which are linked to metabolic syndrome.31 It has been
shown that GIP is overproduced at the proximal gut and its
response to food is downregulated in T2DM patients.32 By
contrast, the production of GLP-1,33 mainly distal gut hor-
mones, is deficient. It is suggested that an excessive prox-
imal absorption due to dietary interventions, such as
refining or liquefying, could be the cause for these enter-
ohormonal disorders.31 GLP-1 is now being used in the clinic
to enhance insulin secretion and improve glycemic control
in T2DM. However, the GLP-1 analogs have several side ef-
fects, such as weight loss and GI discomfort.
We need to look at the change of GIP secretion after the
surgery. GIP is released from intestinal K cells and the
majority of these are located in the foregut-duodenum and
proximal part of the jejunum. GIP is secreted in response to
nutrients ingested, especially glucose or fat.34 We provided
complete exclusion of the foregut, so there was minimal
chance to stimulate K cells in the duodenum and proximal
jejunum by ingested nutrients after the surgery.
A further important consideration is the significance of
decreased GIP secretion. Many studies provide unequivocal
support for the role of GIPas an incretin hormone and suggest
a role of GIP in an early pathophysiologic step that could lead
to impaired glucose tolerance and T2DM.35 However, in
T2DM, plasma glucagon fails to decrease properly or, para-
doxically, can even increase after oral glucose ingestion.36
This lack of glucagon suppression contributes significantly
to postprandial hyperglycemia in T2DM patients.37,38 Also,
GIP is unable to further amplify the insulinotropic and
glucose-lowering effects of GLP-1 in T2DM patients. Besides,
the suppression of glucagon byGLP-1 is antagonized byGIP.39
Therefore, decreased postprandial GIP level is much more
helpful to control hyperglycemia.
We can find another importance of decreased GIP from
the BPD procedure. While RYGB does not affect insulin
resistance, but increases insulin secretion via the stimula-
tion of nutrient-mediated incretin secretion, BPD induces a
full recovery of insulin resistance. Part of the results
observed after BPD can be attained by the reduction of GIP
secretion and the simultaneous increase of GLP-1.40
Interestingly, the action of incretin has a greater effect
on lowering serum glucose in Asian diabetic patients with
BMI < 30 kg/m2.41 Also, a recent gene study demonstrated a
nonsynonymous polymorphism of the GIP gene, which is
shown in East Asians more commonly compared to other
ethnic groups.42 In other words, there could have been
ethnical differences in secretion and action of incretin.
The relationship between the bypassed limb length and
the T2DM remission is clear.43 No extreme weight loss
occurred in nonobese cases, and the patient’s BMI should
not be the only factor when considering surgery. Thus,
nonobese diabetic patients should also be candidates for
metabolic surgery.19,44e46
This study was conducted in 12 Korean T2DM patients,
whose range of BMI was from 23.1 kg/m2 to 30.0 kg/m2.
This ranges from upper normal to overweight, based on the
WHO definition of obesity. However, this ranges from
overweight to mild obesity according to the Asian criteria of
obesity. Most patients were able to advance to their usualdiet without early satiety 2 weeks after the surgery. This
could be achieved because of larger and longer gastric
pouches relative to RYGB. The length of the bypassed limbs
was 200 cm from the ligament of Treitz. There were no
nutritional side effects, such as severe diarrhea, hypo-
proteinemia, or malnutrition. Also, we were able to achieve
procedural safety and simplicity by performing single
anastomosis. The achievement of reversibility was also
possible. The small gastric pouch in the classic loop gastric
bypass of Mason was high in the abdomen, close to the
gastroesophageal junction. This could lead to esophagitis
because of bile refluxes.47 It has been considered as ul-
cerogenic, or even potentially oncogenic. However, we
placed the jejunal loop much lower around the stomach,
just proximal to the pyloric ring. Also, we made the
anchoring suture at the mid-portion of the gastric pouch
with the jejunum, so that we were able to make parallel
lines between the pouch and the efferent loop. No patients
suffered from a gastric ulcer after the surgery. We reduced
bile refluxes through more physiologic positions of the
anastomosis and the direction of bile flow.
All 12 patients showed significantly increased GLP-1
levels and decreased GIP levels 1 month after the surgery,
regardless of the duration of T2DM. Similar changes are
seen after malabsorptive procedures such as BPD.
We need to discuss the possible reasons why the fasting
blood glucose remained unchanged 1 month after the sur-
gery. There are two major causes of increased fasting blood
glucose in T2DM patients. One is impaired secretion of in-
sulin and the other is increased endogenous glucose pro-
duction. Pancreatic beta cell masses proliferate in response
to GLP-1. It might take a few years for beta cells to pro-
liferate in response to GLP-1.48 After improving secretion of
insulin, the fasting plasma glucose would be reduced. One
month after the surgery was a short period to show changes
in serum glucose profiles in nonmorbid obese patients.
However, what we mainly wanted to highlight in this study
was that the changes of incretin levels in nonmorbid T2DM
patients had occurred soon after the surgery. Also, human
bodies react to physical stress such as surgery and trauma
by increasing metabolism. That is, there are phenomena
such as increased glycolysis, gluconeogenesis, proteolysis,
or lipolysis in liver, muscle, and adipose tissue to react to
physical stress and to retain homeostasis. Glucagon release
also increases. As a result, blood glucose levels can be
increased soon after the surgery, unless regulatory hor-
mones act properly.
By contrast, postprandial serum glucose level has shown
to be decreased soon after the surgery in nonmorbid T2DM
patients. We think this is because a rapid decrease of GIP
secretion occurs after the surgery. It has become known
that decreased GIP secretion plays a part in glucose control
through suppression of glucagon after meal.36,37
Patients showed a slight decline in weight immediately
after the surgery because of the decreased food intake and
caloric restrictions. However, a long-term evaluation of
weight change is needed, since the patients recovered the
amount of intake about 1e2 weeks after the surgery
without early satiety.
This study has several limitations. The sample size was
small and there was no control group. The control group
could have been another surgical group or a group treated
136 M.J. Kim et al.with other medical interventions, such as a low caloric
diet, GLP-1 agonists, or DPP-IV inhibitors. Also, small
changes in body weight owing to the decreased intake and
caloric restrictions could affect the change of incretin
levels. In addition, other possible mechanisms due to the
anatomical rearrangement of the procedure, e.g., alteration
of bile flow, rerouting of the gastrointestinal tract, etc.,
could affect the results. A diet-controlled, matched long
term study with a larger series needs to be conducted in the
future.
These data clearly showed significant increased insulin
secretion and changes in incretin levels in nonmorbid obese
patients. The results tended to be independent of the
duration of diabetes. There is a positive relation between
the duration of disease and the changes in total GLP-1
levels (r Z 0.428, p Z 0.166) and GIP (r Z 0.145,
pZ 0.653), but there is no significance. However, there is a
positive relation between the duration of disease and the
change in active GLP-1 (r Z 0.622, p Z 0.031). The single
anastomosis gastric bypass (SAGB) surgery might be able to
induce early beneficial hormonal changes and to be a very
efficient surgical therapy for rapid glycemic control in
nonmorbidly obese patients with T2DM.
Our major findings are a significant increase of GLP-1
and a decrease of GIP, along with improved diabetes con-
trol soon after surgery in nonmorbidly obese T2DM patients.
We are going to identify long-term changes of these data
excluding the effects of diet and weight loss. We are also
going to follow up for a longer period, to reveal the dura-
bility of these changes.5. Conclusion
Soon after the single anastomosis gastric bypass in nonobese
T2DM patients, control of T2DM could be achieved. The
enteroinsular impairment of T2DM is markedly improved.
Early diabetes control could be a consequence of changes in
the enteroinsular axis, particularly in the incretins.Acknowledgments
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